About Second Sight Medical Products (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

Miscellaneous

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) issued its quarterly earnings results on Wednesday, March, 7th. The medical device company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. The medical device company earned $3.10 million during the quarter, compared to analysts' expectations of $1.98 million. Second Sight Medical Products had a negative net margin of 358.06% and a negative return on equity of 169.01%. Second Sight Medical Products's quarterly revenue was up 333.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.24) EPS. View Second Sight Medical Products' Earnings History.

When will Second Sight Medical Products make its next earnings announcement?

Where is Second Sight Medical Products' stock going? Where will Second Sight Medical Products' stock price be in 2018?

1 Wall Street analysts have issued 1 year price objectives for Second Sight Medical Products' shares. Their predictions range from $5.00 to $5.00. On average, they expect Second Sight Medical Products' stock price to reach $5.00 in the next year. View Analyst Ratings for Second Sight Medical Products.

What are Wall Street analysts saying about Second Sight Medical Products stock?

Here are some recent quotes from research analysts about Second Sight Medical Products stock:

1. According to Zacks Investment Research, "Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. " (1/8/2018)

2. HC Wainwright analysts commented, "We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway." (8/8/2017)

David Murray Jacques, Vice President - Research & Development (Age 54)

William J. Link Ph.D., Independent Director (Age 71)

Aaron Mendelsohn, Independent Director (Age 66)

Matthew Jonathan Pfeffer, Independent Director (Age 60)

Gregg Williams, Independent Director (Age 58)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

Has Second Sight Medical Products been receiving favorable news coverage?

Media stories about EYES stock have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.24 on Accern's scale. They also assigned news stories about the medical device company an impact score of 45.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.70%), Millennium Management LLC (0.21%), HBK Sorce Advisory LLC (0.17%) and Sigma Planning Corp (0.13%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams and Robert J Greenberg. View Institutional Ownership Trends for Second Sight Medical Products.

Which institutional investors are selling Second Sight Medical Products stock?

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $1.96.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $111.34 million and generates $7.96 million in revenue each year. The medical device company earns $-28,520,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Second Sight Medical Products employs 110 workers across the globe.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

MarketBeat Community Rating for Second Sight Medical Products (EYES)

MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.